In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment.
1、Platform Overview
Designed for the study of complement-dependent cytotoxicity, InnoModels' CDC platform provides researchers with an experimental system that is closer to real physiological conditions by simulating the complex immune microenvironment in vivo. The platform can support the combination of various types of tumor cells and immune cells, including tumor cell lines, primary tumor cells and genetically engineered cell lines, to meet the diverse experimental needs of researchers. Meanwhile, the platform also supports the use of peripheral blood mononuclear cells (PBMC) from commercial sources and clinical patients to ensure the accuracy and reliability of experimental results.
2、Technology Features
High-throughput automation technology: The platform adopts high-throughput automation technology, which is capable of handling multiple samples at the same time and realizing large-scale data collection and analysis, greatly improving the experimental efficiency and data processing capability.
Flow cytometry: With advanced flow cytometry technology, the platform is able to monitor and record cell changes in real-time during experiments, effectively differentiate target cells, and accurately count and calculate the proportion of apoptotic cells, providing researchers with accurate and reliable data support.
LDH assay: In order to assess the experimental effect more comprehensively, the platform also provides LDH assay to detect the activity of tumor cells, providing researchers with multi-dimensional experimental data.
Highly customizable: The platform is highly customizable and can be customized according to the specific needs of the researcher, including cell type, drug treatment, experimental time and other aspects to meet the diverse needs of different researchers.

3、 Application Prospects
InnoModels' CDC platform has a wide range of application prospects in cancer treatment research. First, it can quickly and accurately assess the CDC effects of potential therapeutic drugs, providing important information for drug development. Secondly, the platform can deeply explore the molecular mechanism of CDC, reveal the interaction between therapeutic drugs and the immune system, and provide a theoretical basis for the development of new drugs. In addition, based on the immune characteristics of patients, the platform can customize treatment plans to improve the relevance and efficacy of treatment. Finally, the platform can also discover and validate biomarkers related to the effects of CDC, providing a basis for clinical translation.
4、Conclusion
The launch of the CDC platform of InnoModels Biotechnology marks a solid step forward in the field of tumor immunotherapy research. In the future, with the continuous development of the biomedical field, the platform will play a greater role in promoting the progress of cancer treatment and providing patients with more personalized and precise treatment plans. We believe that the future of tumor immunotherapy will be brighter with the continuous efforts of InnoModels Biotechnology.